Terumo Corporation (ADR)

General ticker "TRUMY" information:

  • Sector: Health Care
  • Industry: Medical - Instruments & Supplies
  • Capitalization: $21.1B (TTM average)

Terumo Corporation (ADR) follows the US Stock Market performance with the rate: 6.2%.

Estimated limits based on current volatility of 1.5%: low 14.15$, high 14.58$

Factors to consider:

  • Company pays dividends (semi-annually): last record date 2026-03-31, amount 0.08$ (Y1.11%)
  • Current price 17.3% below estimated low
  • Earnings for 15 months up through Q1 (+1 year) exceed our estimates

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2025-03-31 to 2027-03-31

  • 2025-03-31 to 2026-03-31 estimated range: [15.60$, 22.85$]
  • 2026-03-31 to 2027-03-31 estimated range: [17.44$, 25.03$]

Financial Metrics affecting the TRUMY estimates:

  • Positive: with PPE of 35.8 at the end of fiscal year the price was neutral
  • Positive: 4.90 < Operating cash flow per share per price, % of 5.09
  • Positive: 11.29 < Operating profit margin, % of 15.22
  • Positive: Interest expense per share per price, % of 0.15 <= 0.33
  • Positive: Inventory ratio change, % of -1.59 <= -1.30
  • Positive: 5.14 < Return on assets ratio (scaled to [-100,100]) of 6.01
  • Positive: 69.38 < Shareholder equity ratio, % of 74.85 <= 81.92
  • Positive: -16.84 < Industry operating profit margin (median), % of -10.05
  • Negative: Investing cash flow per share per price, % of -1.99 <= -1.23
  • Positive: 0.90 < Industry operating cash flow per share per price (median), % of 1.23

Similar symbols

Short-term TRUMY quotes

Long-term TRUMY plot with estimates

Financial data

YTD 2023-03-31 2024-03-31 2025-03-31
Operating Revenue ¥820,209.00MM ¥921,863.00MM ¥1,036,171.00MM
Operating Expenses ¥702,877.00MM ¥781,767.00MM ¥878,503.00MM
Operating Income ¥117,332.00MM ¥140,096.00MM ¥157,668.00MM
Non-Operating Income ¥-1,195.00MM ¥733.00MM ¥-3,094.00MM
Interest Expense ¥4,016.00MM ¥2,775.00MM ¥6,247.00MM
R&D Expense ¥61,600.00MM ¥0.00MM ¥0.00MM
Income(Loss) ¥116,137.00MM ¥140,829.00MM ¥154,574.00MM
Taxes ¥26,811.00MM ¥34,455.00MM ¥37,595.00MM
Net Income(Loss)* ¥89,325.00MM ¥106,374.00MM ¥116,978.00MM
Stockholders Equity ¥1,111,063.00MM ¥1,327,090.00MM ¥1,368,535.00MM
Inventory ¥249,618.00MM ¥286,599.00MM ¥294,385.00MM
Assets ¥1,602,225.00MM ¥1,831,402.00MM ¥1,828,393.00MM
Operating Cash Flow ¥117,536.00MM ¥146,330.00MM ¥210,802.00MM
Capital expenditure ¥72,173.00MM ¥78,774.00MM ¥82,365.00MM
Investing Cash Flow ¥-59,121.00MM ¥-81,472.00MM ¥-82,481.00MM
Financing Cash Flow ¥-86,559.00MM ¥-62,079.00MM ¥-108,766.00MM
Earnings Per Share** ¥59.50 ¥71.50 ¥79.01
Ordinary share to ADR 1.00x 1.00x 1.00x

* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.